Skip to contentH
HCW Biologics Inc.
H
HCWBHCW Biologics Inc. Q1 2024 · 10-Q
Revenue$1.13M$1.13M+2,590.1% vs Q1 2023 Net Income-$7.47M-$7.47MN/M vs Q1 2023 EPS Diluted-$0.20-$0.20N/M vs Q1 2023 Gross Profit$614,747+4,805.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
HCW Biologics Inc. · CIK 1828673 · Engraved from SEC EDGAR
Operating Cash Flow-$3,603,870N/M Free Cash Flowderived-$3,733,579N/M Margins · derivedGross margin54.6%+24.6 pt vs Q1 2023
Operating margin-665.1%+12133.8 pt vs Q1 2023
Net margin-662.8%+11444.0 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end